NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
– Initiation of an IND enabling toxicology study for the first program under the 2018 collaboration oncytokine derivatives earns a $15 million milestone payment from Merck SOUTH SAN FRANCISCO, Calif., April 15, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 8, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
SOUTH SAN FRANCISCO, Calif., March. 22, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
- Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway into the second half of 2023 - Four antibody-drug conjugate programs are now in the clinic that were discovered through Sutro’s proprietary and integrated...
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
South San Francisco, Calif., Dec. 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
South San Francisco, Calif., Dec. 8, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
South San Francisco, Calif., Dec. 7, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...